ES2167619T3 - Derivados de 1-(piperidinil-1,2-disustituido)-4-(imidazol condensado)-piperidina. - Google Patents

Derivados de 1-(piperidinil-1,2-disustituido)-4-(imidazol condensado)-piperidina.

Info

Publication number
ES2167619T3
ES2167619T3 ES96944693T ES96944693T ES2167619T3 ES 2167619 T3 ES2167619 T3 ES 2167619T3 ES 96944693 T ES96944693 T ES 96944693T ES 96944693 T ES96944693 T ES 96944693T ES 2167619 T3 ES2167619 T3 ES 2167619T3
Authority
ES
Spain
Prior art keywords
rent
replaced
het
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96944693T
Other languages
English (en)
Inventor
Frans Eduard Janssens
Joseph Elisabeth Leenaerts
Roosbroeck Yves Emiel Mari Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2167619T3 publication Critical patent/ES2167619T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ESTA INVENCION HACE REFERENCIA A LOS COMPUESTOS DE FORMULA (I), LAS FORMAS N ENTE ACEPTABLES Y LAS FORMAS ESTEREOQUIMICAMENTE ISOMERICAS DE LAS MISMAS, EN LA QUE N ES 0,1 O 2; M ES 1 O 2, CON LA CONDICION DE QUE SI M ES 2, ENTONCES N ES 1; =Q ES =O O =NR3; X ES UN ENLACE COVALENTE O O-, -S-, -NR3; R1 ES AR1, AR1 C1-6 ALQUILO O DI(AR1)C1-6 ALQUILO, EN LA QUE CADA GRUPO ALQUILO C1-6 ESTA OPCIONALMENTE SUSTITUIDO; R2 ES AR2, AR2 C1-6 ALQUILO, HET O HET C1-6 ALQUILO; R3 ES HIDROGENO O C1-6 ALQUILO; L ES UN DERIVADO PIPERIDINO DE FORMULA (A-1) O UN DERIVADO ESPIROPIPERIDINO DE FORMULA (A-2); AR1 ES FENILO O FENILO SUSTITUIDO; AR2 ES NAFTALENILO; FENILO O FENILO SUSTITUIDO; Y HET ES UN HETEROCICLO MONOCICLICO O BICICLICO; CADA HETEROCICLO MONOCICLICO Y BICICLICO PUEDE OPCIONALMENTE ESTAR SUSTITUIDO EN UN ATOMO DE CARBONO; COMO ANTAGONISTAS DE SUSTANCIA P; SU PREPARACION, COMPOSICIONES QUE LOS CONTIENEN Y SU EMPLEO COMO UN MEDICAMENTO.
ES96944693T 1995-12-27 1996-12-20 Derivados de 1-(piperidinil-1,2-disustituido)-4-(imidazol condensado)-piperidina. Expired - Lifetime ES2167619T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95203652 1995-12-27

Publications (1)

Publication Number Publication Date
ES2167619T3 true ES2167619T3 (es) 2002-05-16

Family

ID=8221024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96944693T Expired - Lifetime ES2167619T3 (es) 1995-12-27 1996-12-20 Derivados de 1-(piperidinil-1,2-disustituido)-4-(imidazol condensado)-piperidina.

Country Status (29)

Country Link
US (1) US6251894B1 (es)
EP (1) EP0843679B1 (es)
JP (1) JP4097043B2 (es)
KR (1) KR100485147B1 (es)
CN (1) CN1066733C (es)
AR (2) AR005278A1 (es)
AT (1) ATE208392T1 (es)
AU (1) AU716071B2 (es)
BR (1) BR9612307A (es)
CA (1) CA2238817C (es)
CY (1) CY2271B1 (es)
CZ (1) CZ295861B6 (es)
DE (1) DE69616802T2 (es)
DK (1) DK0843679T3 (es)
EA (1) EA001374B1 (es)
ES (1) ES2167619T3 (es)
HU (1) HU229766B1 (es)
IL (2) IL124642A (es)
MY (1) MY117680A (es)
NO (1) NO310916B1 (es)
NZ (1) NZ325845A (es)
PL (1) PL183767B1 (es)
PT (1) PT843679E (es)
SI (1) SI0843679T1 (es)
SK (1) SK283540B6 (es)
TR (1) TR199801210T2 (es)
TW (1) TW382017B (es)
WO (1) WO1997024356A1 (es)
ZA (1) ZA9610889B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527186B (en) 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
AU1146099A (en) 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
HK1043128B (zh) 1998-12-19 2007-01-19 詹森药业有限公司 抗组胺的螺环化合物
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
CN100491378C (zh) 2001-06-12 2009-05-27 詹森药业有限公司 新的取代四环咪唑衍生物,其制备方法,包含它们的药物组合物及它们作为药物的用途
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
HRP20040427B1 (hr) * 2001-11-23 2012-09-30 Janssen Pharmaceutica N.V. Uporaba antihistaminika za akutno smanjenje povi‹enog intrakranijalnog tlaka
WO2003050123A1 (en) * 2001-12-10 2003-06-19 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
RU2301806C2 (ru) * 2002-01-16 2007-06-27 Янссен Фармацевтика Н.В. Прукалоприд-n-оксид
US6995153B2 (en) * 2002-01-18 2006-02-07 Kyorin Pharmaceutical. Co., Ltd. Fused bicyclic pyrimidine derivatives
EP1489083B1 (en) * 2002-03-26 2007-06-06 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivative as tachykinin receptor antagonist
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
US7514424B2 (en) * 2002-12-23 2009-04-07 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
NZ556629A (en) 2005-03-03 2010-04-30 Janssen Pharmaceutica Nv Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
DE602006016244D1 (de) 2005-03-08 2010-09-30 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
US20100184819A1 (en) * 2007-07-19 2010-07-22 Robert Vink Method for reducing intracranial pressure
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
EP3758688B1 (en) 2018-02-26 2024-03-27 Ospedale San Raffaele S.r.l. Nk-1 antagonists for use in the treatment of ocular pain
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
US5393753A (en) * 1990-10-10 1995-02-28 Schering Corporation Substituted imidazobenzazepines
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
EP0708776B1 (en) * 1993-07-13 2001-01-03 Janssen Pharmaceutica N.V. Antiallergic imidazoazepines
WO1996002503A1 (en) 1994-07-15 1996-02-01 Meiji Seika Kabushiki Kaisha Novel compound having platelet aggregation inhibitor effect
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives

Also Published As

Publication number Publication date
TW382017B (en) 2000-02-11
SK83098A3 (en) 1999-01-11
MY117680A (en) 2004-07-31
SK283540B6 (sk) 2003-09-11
KR19990076715A (ko) 1999-10-15
PL327136A1 (en) 1998-11-23
US6251894B1 (en) 2001-06-26
KR100485147B1 (ko) 2005-09-13
HU229766B1 (hu) 2014-06-30
NO982405L (no) 1998-08-19
IL124641A (en) 2001-11-25
BR9612307A (pt) 1999-07-13
IL124642A0 (en) 1998-12-06
EP0843679B1 (en) 2001-11-07
JP2000506503A (ja) 2000-05-30
PL183767B1 (pl) 2002-07-31
CN1066733C (zh) 2001-06-06
EA199800603A1 (ru) 1998-12-24
HUP9903948A3 (hu) 2000-04-28
CY2271B1 (en) 2003-07-04
EP0843679A1 (en) 1998-05-27
WO1997024356A1 (en) 1997-07-10
AR005278A1 (es) 1999-04-28
PT843679E (pt) 2002-04-29
JP4097043B2 (ja) 2008-06-04
ZA9610889B (en) 1998-06-23
TR199801210T2 (xx) 1999-10-21
CZ186598A3 (cs) 1998-11-11
CN1206417A (zh) 1999-01-27
ATE208392T1 (de) 2001-11-15
CA2238817A1 (en) 1997-07-10
EA001374B1 (ru) 2001-02-26
AU1308697A (en) 1997-07-28
HK1011206A1 (en) 1999-07-09
IL124641A0 (en) 1998-12-06
IL124642A (en) 2002-08-14
NO310916B1 (no) 2001-09-17
HUP9903948A2 (hu) 2000-03-28
NZ325845A (en) 1999-06-29
AR051817A2 (es) 2007-02-14
NO982405D0 (no) 1998-05-27
SI0843679T1 (en) 2002-06-30
DK0843679T3 (da) 2002-02-25
CA2238817C (en) 2006-10-17
DE69616802T2 (de) 2002-07-04
DE69616802D1 (de) 2001-12-13
AU716071B2 (en) 2000-02-17
CZ295861B6 (cs) 2005-11-16

Similar Documents

Publication Publication Date Title
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
AR009321A1 (es) Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen y compuestos intermediarios.
BR0316609A (pt) Sinomenina e compostos de sinomenina, sìntese e uso
ES2056190T3 (es) Derivados de 4(4-fenil-1-piperazinil)fenoles, inhibidores de 5-lipoxigenasa.
ES2120404T3 (es) Heteroarilamino- y heteroariloxipiridinaminas y compuestos afines, un procedimiento para su preparacion y su uso como medicamentos.
SE9904652D0 (sv) Novel Compounds
ES2143238T3 (es) Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4.
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
ES2146741T3 (es) Derivados de rapamicina utiles como inmunosupresores.
KR900700486A (ko) 신규한 벤조피리도 피페리딘, 피페리딜리덴 및 피페라진 화합물, 조성물, 제조방법 및 이용방법
MEP12708A (en) Derivatives of n-[phenyl (alkylpiperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
MY117680A (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)- piperidine derivatives
DK0691128T3 (da) Anvendelse af CRF-antagonister
ATE206122T1 (de) Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
PA8495101A1 (es) Derivados de 13-metileritromicina
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
ES2062425T3 (es) Piridinas, procedimientos de preparacion y medicamentos que las contienen.
ES2110260T3 (es) Androstenonas.
PY0125402A (es) Derivados de puente de piperazina
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
BR9812970A (pt) Derivado de tetraidropiridopirimidinona 3-substituìda, e, uso deste
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
CO4520266A1 (es) Derivado de 1,3-oxazin-4-ona, el herbicida que lo contiene y los productos intermedios para prepararlo